Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sodium thiosulfate - Fennec Pharmaceuticals

Next Previous
Drug Profile

Sodium thiosulfate - Fennec Pharmaceuticals

Alternative Names: PEDMARK; PEDMARQSI; Sodium hyposulfite; STS - Fennec

Latest Information Update: 05 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oregon Health & Science University
  • Developer Fennec Pharmaceuticals
  • Class Antidotes; Antituberculars; Chemoprotectants; Thiosulfates; Vasodilators
  • Mechanism of Action Antioxidants; Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity No
  • Available For Licensing Yes - Sensorineural hearing loss

Highest Development Phases

  • Marketed Sensorineural hearing loss

Most Recent Events

  • 02 Dec 2025 Efficacy, adverse events and pharmacokinetic data from a phase II trial in Sensorineural hearing loss released by Fennec Pharmaceuticals
  • 27 Nov 2025 Sodium thiosulfate - Fennec Pharmaceuticals is available for licensing in Japan as of 27 Nov 2025. www.fennecpharma.com
  • 21 Oct 2025 City of Hope Medical Center in collaboration with National Cancer Institute plans a phase I trial for Sensorineural hearing loss (In adults, prevention, Chemotherapy induced) in USA in February 2026 (NCT07218913)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top